Neuro–immune crosstalk in the tumor microenvironment: mechanisms and therapeutic implications for cancer immunotherapy Authors: Zezhi Fan, Na Wang, Bo Zhang, Kaiyuan Deng, Jiangjiang Fu, Li Ma, Junyi Li, Zhifang Xu, Yi Guo Published: 2026 ABSTRACT The nervous system is a critical regulator of the tumor microenvironment (TME), extending beyond structural innervation to influence tumor initiation, progression, and therapeutic response. Neural regulation operates through synapse-like interactions and paracrine, neurotransmitter-mediated, and electrochemical signaling, thereby shaping both malignant and stromal compartments. These signals modulate immune-cell phenotypes, promote T-cell exhaustion, and expand immunosuppressive populations, thereby contributing to immune evasion and resistance to immunotherapy. Emerging evidence highlights bidirectional crosstalk, whereby neural activity supports tumor growth, metastasis, metabolic reprogramming, and immune suppression, while tumor-derived signals reciprocally remodel neural activity. This dynamic crosstalk defines a neuro–immune–tumor regulatory network that represents an important layer of tumor biology. Despite recent advances, how neural, immune, and metabolic pathways are integrated within the TME remains incompletely understood. Cancer neuroscience has therefore emerged as an interdisciplinary field for elucidating these mechanisms and identifying therapeutic vulnerabilities. Targeting the neuro–immune axis through neuromodulation, neuroactive agents, and combination immunotherapy may improve immunotherapy efficacy and advance precision oncology. Introduction Cancer initiation and progression are highly dependent on the dynamic interactions among immune, metabolic, and stromal signals within the tumor microenvironment (TME). Although tumor-infiltrating CD8⁺ T cells possess antitumor potential, they are prone to functional exhaustion under persistent antigen stimulation and immunosuppressive conditions, characterized by reduced effector function and upregulation of immune checkpoint molecules [1]. Consequently, the efficacy of immune checkpoint inhibitors (ICIs) remains limited [2, 3]. Therefore, elucidating the upstream mechanisms that regulate the immune status of the TME is a critical scientific challenge for improving responses to immunotherapy. Recently, the nervous system has emerged as an important regulatory component of the TME. Functional neural infiltration is widespread in tumor tissues and arises from both pre-existing neural networks and tumor-induced neurogenesis [4, 5]. Neurogenic signals directly influence tumor cell behavior and promote disease progression by reshaping the immune microenvironment. For example, norepinephrine inhibits CD8⁺ T cell effector function and promotes exhaustion through β-adrenergic receptors (β-ARs) [6]. In addition, the β2-AR/STAT3 signaling axis enhances the accumulation of myeloid-derived suppressor cells (MDSCs) [7]. Acetylcholine regulates macrophage inflammatory responses through the α7 nicotinic acetylcholine receptor (α7nAChR) [8]. Calcitonin gene-related peptide (CGRP), released by sensory nerves, inhibits dendritic cell (DC) development and impairs T cell function [9]. These studies demonstrate that neurotransmitters and neuropeptides constitute a key molecular basis linking the nervous system with tumor immune regulation [10]. Further studies indicate that neural signals do not act in isolation. Instead, by inducing changes in the expression of inflammatory factors such as IL-6, TNF-α, CCL2, and CXCL12, they drive the recruitment, differentiation, and functional reprogramming of immune cells, thereby forming a cascade regulatory axis involving neurotransmitters, cytokines, and immune cells [11]. At the systemic level, the central nervous system (CNS) and peripheral nervous system (PNS) coordinate to regulate immune responses through the neuroendocrine network. Chronic stress activates the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, induces the release of catecholamines and glucocorticoids, promotes the expansion of regulatory T cells (Tregs) and the accumulation of MDSCs, and inhibits CD8⁺ T cell function [12–14]. In addition, the circadian rhythm system influences the therapeutic response to ICIs by regulating immune cell function and immune checkpoint expression [15]. These findings suggest that the nervous system remodels the immune status of the TME through multilevel mechanisms and forms a bidirectional regulatory network with tumors. Based on these insights, the nervous system integrates immune regulation and inflammatory responses through multilevel mechanisms, thereby forming a regulatory network that supports immune escape within the TME. However, a systematic framework is lacking to elucidate how neural signals achieve convergent regulation among different immune cell subsets and how these signals determine responses to immunotherapy. This review focuses on the role of neuro–immune interactions in tumors, analyzes the mechanisms of neurogenic signaling in immune regulation and tumor progression, and summarizes potential therapeutic strategies targeting the neuro–immune axis, with the aim of providing a theoretical basis for optimizing cancer immunotherapy. Implications of neural homeostasis and plasticity in cancer neuroscience The nervous system plays a central role in maintaining physiological balance by preserving tissue homeostasis, regulating immune responses, and mediating adaptation to environmental stress. In recent years, cancer neuroscience research has demonstrated that tumors are not passive recipients of innervation. Instead, they actively exploit physiological mechanisms of the nervous system—originally involved in the regulation of development, homeostasis, and plasticity—to promote their growth, immune evasion, and treatment tolerance. Therefore, understanding the regulatory mechanisms of neural homeostasis at both the CNS and PNS levels is essential for elucidating the fundamental principles of neuro–immune interactions. CNS The CNS maintains brain tissue homeostasis through neural activity, neurotransmitter release, neurotrophic factor secretion, and neurovascular coupling, and it also regulates inflammatory responses and immune cell function [16, 17]. These mechanisms support neural network function and local immune homeostasis under physiological conditions. However, under tumor conditions, they may become aberrantly activated or reprogrammed, thereby serving as key regulatory drivers of tumor progression. Neural activity–dependent plasticity is a central feature of CNS homeostasis. During both developmental and adult stages, neuronal electrical activity regulates the functions of neural stem cells and glial cells via paracrine factors and synapse-related signaling pathways [18]. Under pathological conditions, this mechanism may be aberrantly exploited, whereby neural activity that normally maintains tissue homeostasis is transformed into signals that support abnormal cell proliferation and adaptive survival. Neurotrophins, such as brain-derived neurotrophic factor (BDNF), not only participate in neural development and synaptic plasticity but also play key regulatory roles in intercellular communication, thereby providing a molecular basis for neural-related regulatory networks. In addition, CNS plasticity occurs throughout the lifespan and is characterized by neural activity–dependent structural and functional remodeling, including the optimization of neuronal connections and the dynamic regulation of myelination [19, 20]. This plasticity also influences immune regulation. For example, neural activity can indirectly modulate inflammatory responses and immune microenvironment homeostasis by regulating the function of oligodendrocyte precursor cells (OPCs) and astrocytes [21, 22]. In the CNS, neurotransmitters not only mediate neuronal communication but also influence inflammatory responses and immune-related cellular states. Classical neurotransmitters, such as γ-aminobutyric acid (GABA) and glutamate, regulate local cellular excitability, glial cell responses, and the release of inflammatory mediators [23–25]. Therefore, aberrant neurotransmitter signaling may not only influence tumor cell behavior but also indirectly modulate immune cell recruitment and function by altering the local inflammatory environment. Neurovascular coupling is also an essential component of CNS homeostasis. Neuronal activity can regulate the entry of peripheral immune cells and soluble factors into the CNS by modulating local blood flow and blood–brain barrier (BBB) function [26, 27]. During tumorigenesis, the permeability and selectivity of the BBB and associated vascular barriers may be altered, leading to the remodeling of local immune surveillance, inflammatory responses, and immune cell infiltration patterns. Collectively, neural activity–dependent plasticity, neurotransmitter and neurotrophic factor signaling, and neurovascular coupling in the CNS constitute a fundamental basis for cancer neuroscience. Tumors can exploit these mechanisms, which normally maintain neural homeostasis, and repurpose them into pathological processes that support tumor growth, inflammatory remodeling, and immune evasion. PNS The PNS connects the CNS with peripheral tissues through sympathetic, parasympathetic, and sensory neural networks and serves as a key regulatory system for maintaining tissue homeostasis and immune balance. Beyond the regulation of organ function, the PNS influences the generation, mobilization, and functional states of immune cells through neurotransmitters, neuropeptides, and neuroendocrine signals, thereby providing a basis for understanding neuro–immune interactions in the peripheral TME. Within the bone marrow hematopoietic stem cell (HSC) niche, sympathetic innervation is considered a key regulatory factor in maintaining hematopoietic homeostasis [28]. Sympathetic release of norepinephrine acts on bone marrow mesenchymal stromal cells (MSCs) via β-ARs (β2-AR and β3-AR), leading to periodic downregulation of the chemokine CXCL12 (SDF-1) and promoting the rhythmic mobilization of HSCs from the bone marrow niche to the peripheral blood [29, 30]. This process exhibits circadian rhythmicity, suggesting that neural signals regulate immune cell production and peripheral distribution in a temporal manner. Abnormal neural function or chronic stress can disrupt this homeostatic regulation. Impaired sympathetic nerve function or nerve ablation leads to defective HSC mobilization and disruption of the hematopoietic microenvironment, whereas β-receptor blockade or aberrant neural signaling alters hematopoietic output and affects immune cell composition [31, 32]. Under pathological conditions, neuroregulation significantly influences immune lineage differentiation. Sustained sympathetic activation alters hematopoietic output by promoting myeloid cell production and affecting immune cell composition [32, 33], while inhibiting lymphoid development and shifting immune lineage balance [34, 35]. Therefore, the PNS regulates the immune system not only at the functional level of mature immune cells but also during the stage of immune cell generation. In addition to hematopoietic regulation, the PNS also contributes to the maintenance of peripheral immune homeostasis through multilevel mechanisms. During the peripheral distribution and mobilization of immune cells, sympathetic nerves regulate vascular endothelial cell function by releasing catecholamines, thereby modulating the expression of adhesion molecules and chemokines and promoting immune cell recruitment to specific tissues. This process exhibits pronounced rhythmicity and is mediated by β-AR signaling [36], suggesting that the nervous system is involved not only in immune cell generation but also in regulating their spatial distribution. At the local tissue level, the PNS precisely regulates inflammatory responses through diverse neural signals. Sympathetic nerves primarily regulate the intensity of inflammation and the activation state of immune cells through catecholamines [37]. The parasympathetic nervous system inhibits the production of pro-inflammatory factors through the cholinergic anti-inflammatory pathway, thereby maintaining immune homeostasis [38]. Sensory nerves detect tissue damage and inflammatory stimuli via neuropeptides and contribute to the shaping of local immune responses [39, 40]. Together, these signals form a highly integrated neuroregulatory network that enables the body to fine-tune immune responses according to varying physiological states. In summary, the nervous system establishes a multilevel regulatory network that maintains immune homeostasis under physiological conditions by controlling immune cell generation, distribution, and local inflammatory responses. During tumorigenesis, this neuroregulatory system, which normally maintains tissue homeostasis, may be reprogrammed to provide a structural and functional framework for neuro–immune–tumor interactions. These multilevel neuro–immune interactions collectively reshape the tumor microenvironment and give rise to immunosuppressive and tumor-promoting states, as summarized in Fig. 1. Fig. 1Neuro–immune crosstalk in the tumor microenvironment and its therapeutic implications. Neural signals from the central, sympathetic, parasympathetic, and sensory nervous systems regulate tumor immunity through neurotransmitters and neuropeptides. These signals modulate dendritic cell function, CD8⁺ T cell activity, regulatory T cell expansion, myeloid-derived suppressor cell accumulation, macrophage polarization, angiogenesis, and cancer-associated fibroblast activation, collectively shaping an immunosuppressive tumor microenvironment. The resulting functional outcomes include tumor progression, metabolic reprogramming, and resistance to immunotherapy. Targeting the neuro–immune axis through neuromodulation, neuroactive drugs, anti-neurogenesis strategies, RNA-based therapies, and combination immunotherapy represents a promising approach to enhance antitumor immunity. This framework underscores the interdisciplinary integration of neuroscience, immunology, and oncology for precision cancer therapy Neuro–immune crosstalk in the tumor microenvironment and its therapeutic implications. Neural signals from the central, sympathetic, parasympathetic, and sensory nervous systems regulate tumor immunity through neurotransmitters and neuropeptides. These signals modulate dendritic cell function, CD8⁺ T cell activity, regulatory T cell expansion, myeloid-derived suppressor cell accumulation, macrophage polarization, angiogenesis, and cancer-associated fibroblast activation, collectively shaping an immunosuppressive tumor microenvironment. The resulting functional outcomes include tumor progression, metabolic reprogramming, and resistance to immunotherapy. Targeting the neuro–immune axis through neuromodulation, neuroactive drugs, anti-neurogenesis strategies, RNA-based therapies, and combination immunotherapy represents a promising approach to enhance antitumor immunity. This framework underscores the interdisciplinary integration of neuroscience, immunology, and oncology for precision cancer therapy Mechanistic basis of neuro–immune crosstalk across anatomical levels Based on the regulatory mechanisms of neural homeostasis described above, neuro–immune–tumor interactions exhibit significant variation across different anatomical levels. In the central nervous system and peripheral tissues, differences in barrier structures, innervation patterns, and immune composition lead to distinct spatial specificity in the regulation of tumor immune microenvironments by neural signals. Thus, dissecting the anatomical and spatial dimensions of this interaction network provides a systematic framework for understanding how the nervous system remodels tumor immune status across diverse tissue environments (Fig. 2 and Table 1). Fig. 2Mechanistic basis of neuro–immune crosstalk across anatomical levels in tumor immunity. A Local neural input directly regulates tumor and immune cell function through neurotransmitters and neuropeptides, including BDNF, norepinephrine, substance P, and acetylcholine, primarily mediated by sympathetic, parasympathetic, and somatic nervous systems and their corresponding receptors (e.g., β-adrenergic receptors, nicotinic and muscarinic acetylcholine receptors, NK1R, and RAMP1). B CNS–derived neurotransmitters, such as glutamate, dopamine, GABA, and 5-HT, modulate peripheral tumor immunity through neuroimmune signaling pathways, influencing immune cell recruitment, activation, and functional polarization within the TME. C Systemic neuroendocrine regulation, mediated by the hypothalamic–pituitary axis, coordinates hormonal signaling (e.g., glucocorticoids, melatonin, thyroid hormones, and sex hormones) to regulate immune responses and reshape tumor–immune interactions across peripheral tissues. Together, these multilevel mechanisms integrate local neural signaling, CNS-mediated neurotransmission, and systemic endocrine regulation to establish a bidirectional neuro–immune–tumor network that drives immune remodeling, tumor progression, and therapeutic responsiveness Mechanistic basis of neuro–immune crosstalk across anatomical levels in tumor immunity. A Local neural input directly regulates tumor and immune cell function through neurotransmitters and neuropeptides, including BDNF, norepinephrine, substance P, and acetylcholine, primarily mediated by sympathetic, parasympathetic, and somatic nervous systems and their corresponding receptors (e.g., β-adrenergic receptors, nicotinic and muscarinic acetylcholine receptors, NK1R, and RAMP1). B CNS–derived neurotransmitters, such as glutamate, dopamine, GABA, and 5-HT, modulate peripheral tumor immunity through neuroimmune signaling pathways, influencing immune cell recruitment, activation, and functional polarization within the TME. C Systemic neuroendocrine regulation, mediated by the hypothalamic–pituitary axis, coordinates hormonal signaling (e.g., glucocorticoids, melatonin, thyroid hormones, and sex hormones) to regulate immune responses and reshape tumor–immune interactions across peripheral tissues. Together, these multilevel mechanisms integrate local neural signaling, CNS-mediated neurotransmission, and systemic endocrine regulation to establish a bidirectional neuro–immune–tumor network that drives immune remodeling, tumor progression, and therapeutic responsiveness Table 1Neuro-related external factors shaping the TMETumor ContextImmune Components AffectedNeuro-related StimulusImmunomodulatory Outcome in TMEColorectal cancerMemory T cellsVagal nerve activationInduces splenic TFF2 secretion, thereby limiting MDSC expansion and supporting immune homeostasisOral squamous cell carcinomaCD4⁺ T, CD8⁺ T, NK cellsCGRP deficiency; chronic adrenergic stressAssociated with reduced tumor burden and impaired CD8⁺ T-cell activationPan-cancerMDSCsβ2-adrenergic stress signalingInhibits T-cell proliferation through STAT3 activation and Fas–FasL interactionPan-cancerMDSCs, DCs, CD8⁺ T cellsThermal stress (temperature variation)Elevated temperature diminishes MDSCs while enhancing antigen-presenting myeloid populations, promoting CD8⁺ T-cell activationPan-cancerNK cellsSurgery-associated stressSuppresses NK cell cytotoxic activity under perioperative stress conditionsLung metastasisT cells, neutrophilsChronic stress exposureReduces T-cell infiltration and enhances NET formation, facilitating metastatic progressionColorectal cancerT cells, MDSCsβ-adrenergic blockade (propranolol)Enhances T-cell infiltration and reduces MDSCs, improving response to anti–CTLA-4 therapyBreast cancerMyeloid cellsVagus nerve stimulationIncreases CD8⁺ T and NK cell abundance while restraining MDSC accumulationPancreatic cancerMyeloid cellsParasympathetic (cholinergic) signalingRegulates CD11b⁺ myeloid cells and TNF-α via CHRM1-dependent pathways, influencing tumor stemnessNSCLCCD8⁺ T cellsEmotional distressCorrelates with reduced responsiveness to immune checkpoint blockade therapyPan-cancerCD4⁺/CD8⁺ T cells, NK cellsCircadian rhythmTemporal immune fluctuations modulate multiple immune subsets via endothelial regulation, impacting CAR-T and anti–PD-1 efficacy Table 1Neuro-related external factors shaping the TMETumor ContextImmune Components AffectedNeuro-related StimulusImmunomodulatory Outcome in TMEColorectal cancerMemory T cellsVagal nerve activationInduces splenic TFF2 secretion, thereby limiting MDSC expansion and supporting immune homeostasisOral squamous cell carcinomaCD4⁺ T, CD8⁺ T, NK cellsCGRP deficiency; chronic adrenergic stressAssociated with reduced tumor burden and impaired CD8⁺ T-cell activationPan-cancerMDSCsβ2-adrenergic stress signalingInhibits T-cell proliferation through STAT3 activation and Fas–FasL interactionPan-cancerMDSCs, DCs, CD8⁺ T cellsThermal stress (temperature variation)Elevated temperature diminishes MDSCs while enhancing antigen-presenting myeloid populations, promoting CD8⁺ T-cell activationPan-cancerNK cellsSurgery-associated stressSuppresses NK cell cytotoxic activity under perioperative stress conditionsLung metastasisT cells, neutrophilsChronic stress exposureReduces T-cell infiltration and enhances NET formation, facilitating metastatic progressionColorectal cancerT cells, MDSCsβ-adrenergic blockade (propranolol)Enhances T-cell infiltration and reduces MDSCs, improving response to anti–CTLA-4 therapyBreast cancerMyeloid cellsVagus nerve stimulationIncreases CD8⁺ T and NK cell abundance while restraining MDSC accumulationPancreatic cancerMyeloid cellsParasympathetic (cholinergic) signalingRegulates CD11b⁺ myeloid cells and TNF-α via CHRM1-dependent pathways, influencing tumor stemnessNSCLCCD8⁺ T cellsEmotional distressCorrelates with reduced responsiveness to immune checkpoint blockade therapyPan-cancerCD4⁺/CD8⁺ T cells, NK cellsCircadian rhythmTemporal immune fluctuations modulate multiple immune subsets via endothelial regulation, impacting CAR-T and anti–PD-1 efficacy Neuro-related external factors shaping the TME Neuro–immune crosstalk in CNS tumors The CNS exhibits a unique immune regulatory environment, characterized by the BBB, which restricts immune cell entry. Under physiological conditions, the BBB tightly restricts the entry of circulating immune cells and soluble factors into the CNS through tight junctions and selective transport mechanisms, thereby maintaining a distinct immune homeostasis [41]. However, the BBB is not a static barrier but possesses highly dynamic regulatory properties. During immune surveillance, activated T cells can enter the CNS via transendothelial migration mediated by adhesion molecules and chemokine signaling. Under inflammatory or tumor conditions, BBB permeability is further altered, thereby regulating immune cell recruitment and infiltration patterns [42]. Thus, the BBB functions as both a physical barrier and a regulatory interface that shapes immune remodeling in CNS tumors. As a representative CNS tumor, glioma initiation and progression are highly dependent on functional coupling between neural activity and tumor cells. Studies have shown that glioma cells can form synapse-like structures with neurons and receive glutamatergic inputs, thereby inducing tumor cell depolarization and proliferation [43]. At the molecular level, neuronal activity induces the release of BDNF and neuroligin-3 (NLGN3) and activates the PI3K–mTOR signaling pathway, thereby promoting tumor cell growth and survival [44]. In addition, neurotransmitters such as norepinephrine and serotonin enhance tumor cell invasion and migration by regulating TWIST1 and L1CAM/NF-κB signaling pathways [45, 46]. These findings suggest that aberrant neural activity drives tumor progression by directly stimulating tumor cells and by activating microglia-dependent inflammatory programs that suppress antitumor immunity. Neuroinflammation has been recognized as a central mechanism linking neural signaling and tumor immune regulation. In glioma, microglia and infiltrating macrophages dominate the immune compartment, and their activation states are shaped by neuron-derived signals, including glutamate, ATP, and damage-associated molecules [47, 48]. Persistent neural stimulation and tumor-derived cues drive microglia toward an immunosuppressive phenotype characterized by IL-10 and TGF-β secretion and programmed death-ligand 1 (PD-L1) expression, thereby suppressing CD8⁺ T-cell effector function and promoting exhaustion [49–51]. Thus, microglia act as key intermediaries that convert neural activity into immunosuppression in CNS tumors. From a therapeutic perspective, targeting tumor cell proliferation alone may be insufficient to reverse immune escape in CNS tumors. Combined modulation of microglial phenotype, neural activity–dependent factor release, and T cell exhaustion may be more effective in restoring local antitumor immunity. Peripheral immune cells also contribute to neuroinflammation-driven immune remodeling. Neutrophils exhibit significant functional plasticity in glioma, and their phenotype is regulated by the local inflammatory environment: under proinflammatory conditions, they enhance antigen presentation capacity, whereas in an immunosuppressive neuroinflammatory environment, they upregulate molecules such as PD-L1 and VEGF, thereby promoting immune escape and angiogenesis [47, 52]. These findings indicate that neuroinflammation can polarize neutrophils toward an immunosuppressive phenotype by reshaping the local inflammatory milieu. Concurrently, changes in BBB function and meningeal-associated immune pathways regulate immune cell recruitment. Although cranial bone marrow–derived myeloid cells can contribute to the immune composition of CNS tumors [53], this process should be regarded as a form of inflammation-driven immune remodeling rather than a glioma-specific mechanism. Together, neural activity, neuroinflammation, and immunosuppression form a continuous pathological sequence: aberrant neural activity first induces changes in glial reactivity, then remodels local immune composition and function through inflammatory networks, and ultimately establishes an immune niche that supports tumor growth. Peripheral immune-cell involvement depends on dynamic BBB regulation, whereas their recruitment and functional states are shaped by the local neuroinflammatory environment. Therefore, immune remodeling in CNS tumors should be understood as a systemic process driven by neuroinflammation rather than by a single cell type or signaling pathway. Neuro–immune crosstalk in peripheral solid tumors Unlike the CNS, peripheral solid tumors lack strict barrier constraints, and their neuro–immune interactions primarily rely on an open regulatory network composed of sympathetic, parasympathetic, and sensory nerves [54, 55]. Tumor-associated innervation has been observed across a variety of solid tumors, including lung, liver, pancreatic, gastric, colorectal, and prostate cancers [56–58]. Rather than serving merely as structural components, these fibers regulate immune cell function by releasing norepinephrine, acetylcholine, and neuropeptides, thereby modulating the immune status of the TME. For example, in vitro and in vivo studies have demonstrated that the sympathetic neurotransmitter norepinephrine upregulates IL-6 expression in tumor cells [59]. IL-6 promotes tumor cell survival and invasion in an autocrine manner and enhances immunosuppressive functions of MDSCs and tumor-associated macrophages (TAMs) through STAT3-related pathways, thereby acting as a key inflammatory mediator linking tumor cells to the immunosuppressive microenvironment via sympathetic signaling [60–62]. In addition, norepinephrine promotes vascular endothelial growth factor (VEGF) production by activating the hypoxia-inducible factor-1α (HIF-1α) pathway [63], and upregulates matrix metalloproteinases (MMPs) including MMP-2 and MMP-9, thereby enhancing angiogenesis and metastatic potential [64]. These effects have been further validated in vivo models, including melanoma and lung cancer [65]. Similarly, the parasympathetic neurotransmitter acetylcholine induces VEGF and MMP expression and enhances tumor cell survival by stabilizing the anti-apoptotic protein BCL-2 [66]. These findings suggest that autonomic neurotransmitters function as paracrine regulators in the TME and as direct tumor-promoting signaling molecules that contribute to the progression of peripheral solid tumors. The sympathetic nervous system represents the most well-characterized neuroimmune regulatory pathway in peripheral tumors. Norepinephrine acts on multiple immune cell populations through β-ARs, particularly ADRB2, including TAMs, MDSCs, Tregs, CD8⁺ T cells, and natural killer (NK) cells [67]. In myeloid cells, sympathetic signaling induces TAMs to express IL-10, ARG1, and VEGF, while inhibiting the production of proinflammatory cytokines such as TNF-α, IL-1β, and IL-12, thereby shifting them toward an immunosuppressive phenotype [68]. This altered cytokine profile suggests that sympathetic signaling does not merely suppress inflammation but instead redirects it from an antitumor proinflammatory state toward chronic immunosuppression that supports tissue remodeling, angiogenesis, and immune escape. Norepinephrine also enhances the immunosuppressive function of MDSCs and increases the expression of IL-10, PD-L1, ARG1, and NOS2 [69]. At the lymphocyte level, norepinephrine promotes Tregs to express IL-10 and CTLA-4 [70]. Moreover, the antitumor function of CD8⁺ T cells is impaired through reduced production of IL-2 and IFN-γ and upregulation of PD-1 [6]. Additionally, sympathetic signaling reduces the expression of perforin and granzyme in NK cells, thereby impairing their cytotoxic activity [71]. In vivo studies further demonstrate that sympathetic activation promotes tumor growth and metastasis by suppressing CD8⁺ T cell and NK cell function while enhancing TAM infiltration and ARG1 expression [72]. Thus, sympathetic signaling in peripheral tumors primarily acts as a protumor factor that drives the formation of an immunosuppressive TME. Parasympathetic cholinergic signaling exhibits strong context dependence in the regulation of tumor immunity. Acetylcholine modulates immune cell function through nicotinic acetylcholine receptors (nAChRs) and muscarinic acetylcholine receptors (mAChRs) [73]. In general, activation of nAChRs suppresses proinflammatory and antitumor immune responses, including reducing the expression of TNF-α, IFN-γ, IL-1β, and IL-6, while promoting IL-10 secretion by MDSCs [74, 75]. In addition, activation of nAChRs inhibits the cytotoxic activity of CD8⁺ T cells and NK cells. In contrast, certain mAChR-mediated signals enhance IL-2 and IFN-γ production, suggesting that cholinergic signaling can exert opposing immune effects depending on cell type and receptor context [76]. In addition, CD4⁺ T cells and other lymphocytes can produce acetylcholine and participate in local immune regulation [77]. Because immune cells often co-express multiple adrenergic and cholinergic receptors, the overall effect of autonomic signaling on tumor immunity depends on tumor type, immune cell composition, and receptor expression profiles. Sensory nerves are important regulators of the peripheral TME. Tumor-associated sensory nerves regulate local inflammatory responses and immune cell infiltration by releasing neuropeptides and neurotransmitters such as CGRP, substance P, and dopamine [39, 78]. Among these factors, substance P mediates inflammatory signaling through its receptor, neurokinin-1 receptor (NK1R), and promotes the expansion of Tregs and the secretion of the immunosuppressive cytokine IL-10. This process thereby enhances the immunosuppressive state of the TME [79]. In contrast to the predominantly immunosuppressive effects of substance P, dopamine receptor signaling has also been implicated in the regulation of immune-cell function. Previous studies have shown that dopamine receptors are expressed on T lymphocytes and can modulate T-cell activation and signaling pathways through cAMP–CREB-dependent mechanisms [80]. These findings suggest that neurotransmitter networks contribute to the fine regulation of immune homeostasis and may influence antitumor immunity under different microenvironmental conditions. Previous studies have shown that sensory nerve activation inhibits CD8⁺ T cell and NK cell function and promotes the accumulation of immunosuppressive myeloid cells [81]. In some tumor models, ablation of sensory nerves or blockade of neuropeptide signaling enhances antitumor immunity and inhibits tumor growth, suggesting that sensory nerves function not only as conduits for pain signaling but also as key regulatory nodes in tumor immune escape [82]. Similar to sympathetic signaling, sensory nerves also contribute to immune escape by inhibiting effector immune cell function. However, their effects primarily depend on neuropeptide signaling rather than catecholaminergic pathways. Bidirectional feedback also exists between peripheral tumors and the nervous system. Tumor cells secrete nerve growth factor (NGF) or BDNF precursors to induce the ingrowth of sympathetic or sensory nerve fibers into the TME, thereby further enhancing neurogenic immunosuppression [83, 84]. Concurrently, peripheral tumors activate specific central neural circuits via circulating factors or afferent nerve signaling, thereby regulating autonomic output and modulating antitumor immunity. For example, various peripheral tumors in mouse models activate catecholaminergic neurons in the ventrolateral medulla and promote tumor growth by inhibiting CD8⁺ T cell function [85]. Tumor-induced activation of hypothalamic neurons promotes the release of α-melanocyte-stimulating hormone (α-MSH) from the pituitary gland, drives bone marrow MDSCs generation, and suppresses antitumor immunity [86]. In addition, tumor-derived LIF and GAL3 activate the paraventricular nucleus of the hypothalamus and promote the formation of an immunosuppressive TME through sympathetic output [69]. These findings suggest that peripheral tumors induce systemic immune remodeling through a “tumor–central nervous circuit–peripheral immunity” axis. In conclusion, the peripheral nervous system shapes the immune status of the TME through sympathetic, cholinergic, and sensory signaling pathways. The core mechanisms include promoting the immunosuppressive functions of TAMs and MDSCs, enhancing Treg activity, impairing the effector functions of CD8⁺ T cells and NK cells, and amplifying immune escape through tumor-induced neural remodeling and feedback from central neural circuits. Therefore, peripheral nerve–immune–tumor interactions represent not only a key mechanism underlying tumor progression but also a potential therapeutic target for improving responses to immunotherapy. The role of the nervous system in the TME The nervous system shapes the TME through diverse mechanisms, including direct neural signaling, neuroimmune modulation, and systemic neuroendocrine regulation. These processes involve sensory, sympathetic, and parasympathetic pathways, as well as neurological states such as stress and circadian rhythm, collectively influencing tumor progression and response to immunotherapy (Fig. 3). Fig. 3Integrated roles of the nervous system in shaping the tumor microenvironment and antitumor immunity. The nervous system regulates the TME through coordinated actions of the parasympathetic and sympathetic nervous systems, as well as systemic neurological states. Parasympathetic signaling, mediated by the vagus nerve, cholinergic receptors, and TFF2 pathways, modulates myeloid cell function and immune tolerance. Sympathetic signaling drives myeloid cell reprogramming, CD8⁺ T-cell exhaustion, HPA axis activation, and inflammasome signaling, thereby promoting an immunosuppressive microenvironment. In addition, neurological states, including emotional stress, circadian rhythms, and environmental cues, further reshape immune responses and influence tumor progression and therapeutic outcomes. These neural–immune interactions collectively reshape tumor immune phenotypes and influence antitumor immunity and responsiveness to immunotherapy Integrated roles of the nervous system in shaping the tumor microenvironment and antitumor immunity. The nervous system regulates the TME through coordinated actions of the parasympathetic and sympathetic nervous systems, as well as systemic neurological states. Parasympathetic signaling, mediated by the vagus nerve, cholinergic receptors, and TFF2 pathways, modulates myeloid cell function and immune tolerance. Sympathetic signaling drives myeloid cell reprogramming, CD8⁺ T-cell exhaustion, HPA axis activation, and inflammasome signaling, thereby promoting an immunosuppressive microenvironment. In addition, neurological states, including emotional stress, circadian rhythms, and environmental cues, further reshape immune responses and influence tumor progression and therapeutic outcomes. These neural–immune interactions collectively reshape tumor immune phenotypes and influence antitumor immunity and responsiveness to immunotherapy Sensory nerve fibers in the TME CGRP and substance P, released by peripheral sensory nerve fibers, are involved in the perception and regulation of immune responses [87]. Among these, CGRP is a key neurotransmitter that mediates inflammatory responses through the receptor activity-modifying protein 1 (RAMP1) signaling pathway [88]. Studies have shown that, compared with wild-type (WT) mice, CGRP-deficient mice exhibit significantly reduced tumor volume and increased infiltration of CD4⁺ T cells, CD8⁺ T cells, and NK1.1⁺ cells in tumor tissues [89]. These results suggest that CGRP plays a critical role in regulating the tumor immune microenvironment. Mechanistically, CGRP activates the cAMP-dependent signaling pathway through its receptor complex RAMP1–CALCRL, thereby directly enhancing the immunosuppressive function of Tregs, including upregulation of IL-10 expression and inhibition of effector T cell proliferation [90, 91]. In addition, CGRP indirectly promotes Treg expansion by regulating DCs maturation, thereby contributing to a Tregs-dominated immunosuppressive microenvironment [9]. This immunosuppressive state limits the antitumor function of effector T cells and may also weaken immune activation mediated by ICIs [40]. Therefore, CGRP and its associated signaling pathways represent potential therapeutic targets for regulating Treg function and improving immunotherapy efficacy. Sympathetic nervous system in the TME The stress response is an important upstream driver linking the nervous system to tumor immune regulation. Chronic stress activates the SNS and the HPA axis, induces the release of catecholamines and glucocorticoids, and thereby regulates the TME at multiple levels [92]. Although β-adrenergic signaling has been extensively studied in tumor immunity, its functions across different immune cell populations are highly hierarchical and context-dependent. Therefore, it is crucial to analyze sympathetic regulatory mechanisms across multiple dimensions, including myeloid immunity, adaptive immunity, and inflammatory amplification pathways, to better understand their roles in tumor immune escape. Sympathetic signaling establishes a basal immunosuppressive state through myeloid cell reprogramming Sympathetic signaling establishes a basal immunosuppressive state in the TME by reshaping myeloid cell function. Previous studies have shown that β2-AR signaling significantly increases the abundance of MDSCs in tumors and upregulates arginase-I and PD-L1 expression, thereby inhibiting T cell proliferation via STAT3 phosphorylation and Fas–FasL interactions [7]. In addition to quantitative expansion, sympathetic signaling enhances the immunosuppressive capacity of MDSCs by regulating metabolic programs. β2-AR signaling inhibits glycolysis while enhancing oxidative phosphorylation (OXPHOS) and fatty acid oxidation (FAO), thereby maintaining an immunosuppressive phenotype and weakening antitumor immune responses [93]. This metabolic reprogramming supports long-term MDSC survival and limits effector T cell function through metabolic competition. Environmental and physiological stress further amplify these immunosuppressive effects. Kokolus et al. demonstrated that tumor-bearing mice housed under standard room-temperature conditions (22 °C) exhibited significantly greater tumor volume and weight than mice maintained under thermoneutral conditions (30 °C). Importantly, for laboratory mice, 22 °C represents a state of chronic mild cold stress, whereas thermoneutral housing minimizes the need for adaptive thermogenesis and sympathetic activation. This persistent cold-stress condition induces chronic adrenergic activation and increased catecholamine release, thereby creating a physiologically relevant model of environmental stress and providing a mechanistic explanation for the observed immunosuppressive remodeling of the TME. Mechanistically, cold stress promoted the accumulation of CD11b⁺ myeloid cells, including MDSCs, and increased the proportion of dendritic cells with impaired functional maturation, particularly plasmacytoid DCs. Immature DCs exhibited reduced antigen-presenting capacity, resulting in suboptimal T-cell priming and impaired antitumor immune responses [94]. These findings suggest that environmental stress can reinforce sympathetic-mediated immunosuppression by simultaneously expanding suppressive myeloid populations and disrupting effective antigen presentation. Perioperative stress further weakens antitumor immunity by inhibiting NK-cell activity and reducing Th1 cytokine secretion [95]. Therefore, sympathetic signaling establishes a basal immunosuppressive state that supports tumor growth through three complementary mechanisms: quantitative expansion of suppressive myeloid cells, metabolic reprogramming, and functional inhibition of antitumor immune responses. Sympathetic regulation of CD8⁺ T cell exhaustion lineage determines the response to immunotherapy Building on myeloid-mediated immunosuppression, sympathetic signaling further enhances immune escape at the level of adaptive immunity by regulating CD8⁺ T cell exhaustion and differentiation. Recent studies indicate that CD8⁺ T cell exhaustion is not a single terminal state but rather a dynamic, hierarchically organized differentiation process that can be divided into TCF1⁺ exhausted precursor T cells (Tpex) and terminally exhausted T cells (Tex). Tpex cells possess self-renewal capacity and proliferative potential and represent the primary responders to ICIs. In contrast, Tex cells exhibit high expression of inhibitory receptors and an irreversible decline in effector function [96, 97]. Mechanistically, sympathetic-derived catecholamines exert hierarchical regulatory effects on CD8⁺ T cells through distinct receptor pathways. β1-AR signaling is more directly involved in determining CD8⁺ T cell exhaustion and differentiation [6], whereas β2-AR signaling indirectly weakens antitumor immunity primarily by inducing metabolic dysfunction [98]. Animal studies show that ADRB1 knockout or β-blocker treatment preserves the Tpex cell pool and reduces the generation of terminally exhausted T cells [6]. β2-AR signaling also inhibits T cell receptor (TCR) signaling and disrupts metabolic reprogramming, thereby reducing IFN-γ production and cytotoxic activity [99]. Collectively, β1-AR and β2-AR synergistically drive CD8⁺ T cell dysfunction through differentiation control and metabolic inhibition, respectively. At the molecular level, CD8⁺ T cell exhaustion and differentiation are finely regulated by transcription factors such as TOX, Eomes, and T-bet. Among these factors, TOX is considered a key driver of the exhaustion program, and its sustained expression induces chromatin remodeling and stabilizes the exhausted phenotype [100, 101]. Eomes promotes the maintenance of terminal exhaustion [102], whereas T-bet (encoded by TBX21) supports effector functions and limits excessive exhaustion; reduced T-bet expression is typically associated with Tex cell accumulation [103]. This regulatory network constitutes the core molecular basis for the differentiation of Tpex cells into Tex cells [104]. Recent studies further reveal a direct regulatory role of neural signals in this process. Globig et al. (Nature, 2023) demonstrated that β1-AR signaling plays a critical role in CD8⁺ T cell fate decisions. Adrenergic signaling promotes the selective enrichment of TCF1⁺ Tpex cells while inhibiting their differentiation into functional effector cells, thereby leading to inefficient antitumor immune responses. Mechanistically, β1-AR signaling regulates transcriptional and metabolic programs through the cAMP–PKA pathway, thereby disrupting the dynamic balance of the TOX-associated exhaustion network [6]. This finding highlights a critical role of neuro–immune interactions in determining the efficacy of ICIs by reshaping the exhaustion lineage of CD8⁺ T cells. The HPA axis enhances the immunosuppressive network through Treg expansion Sympathetic signaling indirectly suppresses CD8⁺ T-cell function by impairing antigen presentation; catecholamines alter DC function and reduce their capacity to activate CD8⁺ T cells [105, 106]. More importantly, neuromodulation affects the overall functional state of CD8⁺ T cells and directly determines responses to immunotherapy by altering the Tpex-to-Tex ratio. Studies indicate that active β1-AR signaling hinders the maintenance of functional Tpex cells and drives their differentiation into a terminally exhausted state, thereby reducing the efficacy of anti-PD-1 therapy [6]. Blockade of this pathway restores the Tpex pool and enhances immune responses, indicating that PD-1 expression alone is insufficient to capture CD8⁺ T-cell functional heterogeneity. In addition to direct regulation of CD8⁺ T cells, chronic stress enhances immunosuppression through the HPA axis. Glucocorticoids enhance the transcriptional stability of Foxp3 and promote Tregs survival by activating the glucocorticoid receptor (GR). Concurrently, glucocorticoids promote immune cell recruitment to tumor tissues by regulating chemokine axes such as CCL22–CCR4 [107–109]. Therefore, stress-related neuroendocrine signals weaken antitumor immunity at multiple levels through a dual regulatory mode involving suppression of effector immunity and enhancement of immunosuppressive immunity. In contrast, blockade of β2-AR signaling slows tumor progression by enhancing glycolysis and oxidative phosphorylation in tumor-infiltrating lymphocytes and promoting cytokine production. In addition, stress-induced β-AR signaling directly inhibits T cell receptor function [98]. He et al. further reported that chronic stress reshapes the lung microenvironment by reducing T cell infiltration and fibronectin deposition while increasing neutrophil infiltration. In this context, the formation of neutrophil extracellular traps (NETs) promotes lung metastasis, whereas loss of neutrophil-specific glucocorticoid receptors partially reverses this effect [110]. Based on these mechanisms, the translational potential of the β-adrenergic receptor antagonist propranolol in tumor immunotherapy has attracted increasing attention. Propranolol enhances the efficacy of anti-PD-1 immune checkpoint blockade in metastatic melanoma [111]. Additionally, propranolol increases T cell infiltration and reduces MDSCs accumulation, thereby improving the efficacy of anti-CTLA-4 therapy [112]. Collectively, the sympathetic nervous system shapes the persistence of immunosuppression through a multilevel immune regulatory network involving myeloid cells, CD8⁺ T cell exhaustion, and immunosuppressive cell recruitment, thereby playing a key role in determining responses to immunotherapy. Sympathetic signaling, the NLRP3 inflammasome, and Tregs/CD8⁺ T cell immune balance In addition to directly regulating immune cell function through β-ARs, sympathetic signaling may further amplify neuro–immune interactions via inflammasome pathways. Among these mechanisms, the NLRP3 inflammasome serves as a key sensing platform of the innate immune system. It detects cellular stress, metabolic abnormalities, and damage-associated signals and promotes the maturation and release of IL-1β and IL-18 via caspase-1 activation, thereby regulating inflammatory intensity and immune cell function [113]. Chronic sympathetic activation alters the metabolic state of myeloid cells through norepinephrine/β-AR signaling, inducing ROS accumulation, mitochondrial dysfunction, and NF-κB activation, thereby providing conditions for the initiation and activation of the NLRP3 inflammasome [114–116]. This hypothesis is supported by evidence from animal models showing that β-adrenergic blockers inhibit the NLRP3 pathway and that NLRP3 knockdown reverses the associated phenotypes [117]. This process extends neural regulation from single neurotransmitter signaling to a cascade amplification network involving “neurotransmitter–inflammasome–cytokine” interactions. NLRP3-mediated release of IL-1β and IL-18 plays a critical role in maintaining the immune balance between Tregs and CD8⁺ T cells. IL-1β enhances the stability of Foxp3 expression and the immunosuppressive function of Tregs and indirectly promotes Treg expansion by facilitating myeloid cell recruitment and immunosuppressive polarization [118]. In contrast, IL-18 induces CD8⁺ T cells to undergo exhaustion through the IL-2/STAT5/mTOR pathway in the chronic TME, characterized by upregulation of PD-1, TIM-3, LAG-3, and other co-inhibitory receptors, along with reduced effector function [119]. In addition, persistent IL-1β signaling promotes the expansion of MDSCs and M2 TAMs and further suppresses CD8⁺ T cell function through the secretion of IL-10, TGF-β, and ARG1, thereby forming a positive feedback immunosuppressive circuit [120, 121]. Therefore, the sympathetic–NLRP3 inflammasome axis enhances Treg function through IL-1β and directly induces CD8⁺ T cell exhaustion, leading to an increased Tregs/CD8⁺ T cell ratio and the establishment of an immune microenvironment that is unfavorable for responses to ICIs [122]. Parasympathetic nervous system in the TME Current studies on parasympathetic regulation of the immune system primarily focus on the vagus nerve [123]. In breast tumor-bearing mice, vagus nerve activation induced by electroacupuncture regulates serum levels of proinflammatory cytokines IL-1β and TNF-α, increases the abundance of CD8⁺ T cells and NK cells, and inhibits MDSCs accumulation [124]. In a mouse model of orthotopic pancreatic ductal adenocarcinoma (PDAC), subphrenic vagotomy accelerates tumor growth, a process closely associated with TNF-α secretion by TAMs [125]. Another study on spontaneous PDAC formation showed that both subphrenic vagotomy and knockdown of muscarinic receptor type 1 (CHRM1) promote PDAC progression. Mechanistically, muscarinic signaling activates MAPK/EGFR and PI3K/AKT pathways through CHRM1, while cholinergic signaling regulates CD11b⁺ myeloid cells, TNF-α levels, and cancer stem cell status [126]. In addition, cholinergic signaling plays an important role in regulating adaptive immune responses. Previous studies have shown that acetylcholine can activate intracellular signaling pathways, including ERK and STAT3, via the α7nAChR, thereby contributing to the modulation of T lymphocyte function and regulatory T cell activity [127, 128]. Notably, Wang et al. demonstrated that cholinergic stimulation enhances the suppressive capacity of naturally occurring CD4⁺CD25⁺ regulatory T cells by upregulating Foxp3 and CTLA-4 expression, without significantly altering IL-10 or TGF-β1 production [128]. These findings suggest that cholinergic signaling primarily reinforces the immunosuppressive phenotype and functional stability of pre-existing Tregs rather than inducing de novo differentiation from naive CD4⁺ T cells. This process contributes to immune tolerance by modulating antigen-presenting cell activity and reshaping the local immunoregulatory milieu, thereby promoting the establishment of an immunosuppressive microenvironment in inflammation-associated tumors [129]. Consequently, enhanced cholinergic tone within the parasympathetic nervous system may attenuate antitumor immunity and impair responses to ICIs by strengthening Treg-mediated immune suppression and limiting effector T-cell reactivation [77]. Overall, the parasympathetic nervous system contributes to tumor progression by regulating both innate immune cell activity and adaptive immune tolerance, thereby playing a key role in shaping tumor immune escape and influencing immunotherapy efficacy. Furthermore, the vagus nerve regulates memory T cells and mediates the secretion of spleen-derived trefoil factor 2 (TFF2), an anti-inflammatory peptide, thereby inhibiting MDSC expansion. Studies further show that TFF2 overexpression, adenovirus-mediated delivery, or bone marrow–derived expression attenuates colorectal tumorigenesis [130]. Overall, the role of the parasympathetic nervous system in the TME is highly context-dependent and is influenced by tumor type, immune cell composition, and cholinergic receptor subtype distribution. Neurological status in the TME In addition to direct nerve fiber innervation, the functional state of the nervous system profoundly influences the TME through systemic pathways. Emotional distress (ED), including depression and anxiety [131], is closely associated with non-small cell lung cancer (NSCLC), hematological malignancies, and ovarian tumors. Its effects on the TME are supported by emerging evidence [132]. In female patients, pre-diagnosis depression is associated with increased abundance of activated cytotoxic T cells (CD3⁺CD8⁺CD69⁺) and exhausted T cells (CD3⁺Lag3⁺) within tumors. Depression is also associated with increased infiltration of naive and memory B cells (CD20⁺) in high-grade serous carcinomas [133]. In patients with NSCLC, as assessed by the Patient Health Questionnaire-9 and the Generalized Anxiety Disorder 7-item scale, those with ED exhibit shorter median progression-free survival (PFS) and lower objective response rates (ORR) to ICIs [134]. These findings suggest that neuropsychological states regulate responses to antitumor therapy by reshaping immune cell composition and effector functions. In addition, the immune system is tightly regulated by the circadian clock. Immune effector cells such as DCs and CD8⁺ T cells exert circadian antitumor effects through tumor-draining lymph nodes [135]. Wang et al. reported that leukocyte infiltration in tumors exhibits significant diurnal fluctuations, including CD4⁺ T cells, CD8⁺ T cells, NK1.1⁺ cells, CD11b⁺Ly6C⁺ cells, CD11c⁺MHCII⁺ cells, and CD19⁺ cells. These rhythmic changes are primarily regulated by endothelial cells [15]. Notably, human chimeric antigen receptor T cells (CAR-T) cells exhibit superior therapeutic efficacy when infused in the evening. Further studies show that mRNA and protein expression of Pdcd1 (encoding PD-1) in CD8⁺ T cells peak in the morning, suggesting that evening administration of anti-PD-1 therapy may enhance tumor immune activation [15]. Fortin et al. used gut-specific Bmal1 knockout and Apc heterozygous deletion to generate a genetically engineered mouse model of colorectal cancer. Single-cell RNA sequencing was used to analyze the impact of circadian rhythm disruption on immune profiles. The results show significant time-dependent changes in the abundance of cytotoxic CD8⁺ T cells and PD-L1–expressing MDSCs [136]. Furthermore, Tregs migration and function are tightly regulated by circadian rhythms [137]. Circadian genes (such as BMAL1 and CLOCK) drive time-dependent infiltration of Tregs into tumor tissues by regulating endothelial adhesion molecules (such as ICAM-1) and chemokine expression [138]. Circadian disruption leads to abnormal accumulation of Tregs in the TME and enhances immunosuppression, thereby impairing effector T cell function and reducing the time-dependent efficacy of ICIs [136]. In summary, circadian rhythms are involved in the dynamic remodeling of the TME and influence the therapeutic sensitivity to ICIs by coordinating the spatiotemporal distribution of effector and immunosuppressive cells. Therefore, optimizing the timing of ICI administration has significant clinical potential. Novel therapeutic strategies targeting neuro–immune crosstalk in cancer ICIs combined with neuromodulation or tumor denervation Neuromodulation serves as an adjunctive strategy for ICIs, and its therapeutic value depends on its ability to alleviate neurogenic immunosuppression within the TME. Available evidence indicates that strategies targeting sympatho-adrenergic signaling have the greatest translational potential. Mechanistically, β-adrenergic signaling promotes T cell exhaustion, upregulates PD-1/PD-L1 related inhibitory pathways, and enhances the accumulation of immunosuppressive cells such as MDSCs, Tregs, and M2 macrophages [139]. Accordingly, β-blockers, particularly the nonselective agent propranolol, enhance the efficacy of anti-PD-1 or anti-CTLA-4 therapy by reducing PD-1 expression, promoting CD8⁺ effector T cell infiltration, and decreasing MDSCs accumulation. Propranolol combined with anti-CTLA-4 antibodies significantly improves treatment outcomes in murine fibrosarcoma and colorectal cancer models [112]. A retrospective study in metastatic melanoma and a phase Ib/II clinical trial (NCT03384836) further suggest that propranolol combined with pembrolizumab improves objective response rates, accompanied by increased IFN-γ and decreased IL-6 levels, supporting its immunostimulatory effects [112, 140]. However, this combination strategy is not universally effective. A subsequent phase III trial (NCT02362594) failed to improve relapse-free survival in high-risk populations, suggesting that the benefit of β-blockers combined with ICIs depends on tumor type, sympathetic activation, patient stress status, β-receptor expression profiles, and baseline immune characteristics of the TME [139]. In other words, this regimen is more suitable for patients with pronounced adrenergic activation and immune-excluded phenotypes rather than the broader population receiving ICIs. Future studies should avoid using β-blockers as generalized immune sensitizers and instead stratify patients according to nerve fiber density, ADRB2 expression, PD-L1⁺ nerve fiber density, CD8⁺ tumor-infiltrating lymphocyte (TIL) density, and inflammatory profiles. In contrast, sodium channel blockers such as lidocaine primarily demonstrate perioperative anti-inflammatory and antimetastatic potential rather than serving as established ICI-sensitizing agents [141]. In perioperative breast cancer settings, lidocaine reduces the expression of MMP3, NET-related markers, and MPO, suggesting a potential role in lowering postoperative recurrence risk by inhibiting inflammation, NET formation, and the prometastatic microenvironment. However, robust clinical evidence supporting its ability to enhance ICI efficacy remains lacking [142]. Overall, the core objective of combining neuromodulation with ICIs is to identify and reverse neurogenic immunosuppressive mechanisms rather than simply expanding therapeutic combinations. Currently, β-adrenergic blockade combined with ICIs shows promise, although its efficacy is highly population-dependent. However, other neuromodulation strategies, such as lidocaine, remain at the stage of mechanistic exploration or perioperative application. In the future, integrating multi-omics data on innervation status, immune infiltration, and checkpoint expression profiles will enable the development of a neuro-immune classification system to identify patients most likely to benefit from such therapies. The repurposing of neuroactive drugs Repurposing neuroactive drugs offers a novel translational strategy for cancer treatment, and multiple drug classes targeting distinct neural pathways have entered tumor-related research and clinical evaluation (Table 2). However, the effects of different drugs on tumor progression and their associations with antitumor immunity vary substantially. As noted above, β-blockers targeting the sympathoadrenergic pathway, particularly propranolol, represent the most extensively studied drug class. Although preclinical and some clinical evidence suggest that combining β-blockers with ICIs enhances antitumor immunity, recent systematic reviews and meta-analyses indicate that survival benefits are highly heterogeneous across tumor types and study populations, and the overall evidence remains inconsistent [143]. Table 2Clinical translation of neuro-immune-targeted agents in oncologyAgent (class)Neurobiological targetRepresentative malignanciesHighest clinical phaseRepresentative trial identifiersCurrent development statusResearch implicationKey referencesPropranolol (non-selective β-adrenergic blocker)β-adrenergic receptors (β-ARs)Ovarian cancer, colorectal cancer, gastric cancer, esophageal adenocarcinoma, breast cancer, etc.Phase 3NCT00888797, NCT04005365, NCT04682158, NCT02596867, NCT05797966, NCT05979818Completed/recruiting/ongoing/terminated, depending on indicationMost extensively investigated neuro-targeted repurposed agent; primarily evaluated for modulation of sympathetic signaling and tumor-promoting stress responsesKennedy OJ et al., Eur J Cancer 2022 [139]; Hicks BM et al., Ann Oncol 2013 [144]; Fjæstad KY et al., Oncogene 2022 [112]; Gandhi S et al., Clin Cancer Res 2021 [140]Donepezil (acetylcholinesterase inhibitor)Acetylcholinesterase (AChE)Breast cancer, SCLC, head and neck cancer, pancreatic cancerPhase 3NCT01466270, NCT00006349, NCT00656513,Completed or active, depending on tumor typeExplored mainly in cholinergic regulation–related cancer settings; clinical evidence remains tumor-specific rather than broadly generalizableFornalik M et al., Clin Exp Med 2025 [145]; Rapp SR et al., J Clin Oncol 2024 [146]Bethanechol (muscarinic agonist)Muscarinic acetylcholine receptors (mAChRs)Pancreatic cancerPhase 2NCT03572283, NCT05241249Ongoing/recruitingRepresents a strategy targeting cholinergic signaling activation; current evidence is limited to early-phase pancreatic cancer studiesWhite RA et al., Oncologist 2025 [147]; Jaguar GC et al., Radiother Oncol 2015 [148]Lidocaine (voltage-gated sodium channel modulator)Voltage-gated sodium channels (VGSCs)Breast cancer, NSCLC, pancreatic cancer, ovarian cancer, colorectal cancerPhase 4NCT02839668, ChiCTR2000030629, NCT05450055, NCT00236249, NCT01841294Completed/recruiting/ongoing/unknown, depending on settingInvestigated mainly as a perioperative or adjunctive anti-tumor intervention; potential mechanisms include inhibition of neural excitability, inflammation, and metastatic niche formationGaloș EV et al., Br J Anaesth 2020 [149]; Hou YH et al., Drug Des Devel Ther 2021 [150]ONC201 (dopamine receptor antagonist)DRD2/DRD3 antagonistAcute myeloid leukemia, neuroendocrine tumors, endometrial cancer, ovarian/fallopian tube/primary peritoneal cancerPhase 2NCT03932643, NCT03034200, NCT03485729, NCT04055649OngoingRepresents dopamine pathway intervention in oncology; currently under active investigation across both hematologic and solid tumorsAtkins SL et al., Oncologist 2023 [151]; Anderson PM et al., Clin Cancer Res 2022 [152]Fluoxetine (selective serotonin reuptake inhibitor)Serotonin signaling (5-HT)Colorectal cancer, NSCLCPhase 2NCT06225011, NCT00005850Recruiting/completedA representative serotonergic agent under evaluation for possible anti-proliferative and microenvironment-modulating effectsFisch MJ et al., J Clin Oncol 2003 [153]Escitalopram (selective serotonin reuptake inhibitor)Serotonin signaling (5-HT)Pancreatic cancerPhase 2NCT05289830NCT00536172Terminated/completedClinical translation remains preliminary; current evidence does not yet support broad oncologic applicationMusselman D et al., Neuropsychopharmacology 2013 [154]; Lydiatt WM et al., JAMA Otolaryngol Head Neck Surg 2013 [155] Table 2Clinical translation of neuro-immune-targeted agents in oncologyAgent (class)Neurobiological targetRepresentative malignanciesHighest clinical phaseRepresentative trial identifiersCurrent development statusResearch implicationKey referencesPropranolol (non-selective β-adrenergic blocker)β-adrenergic receptors (β-ARs)Ovarian cancer, colorectal cancer, gastric cancer, esophageal adenocarcinoma, breast cancer, etc.Phase 3NCT00888797, NCT04005365, NCT04682158, NCT02596867, NCT05797966, NCT05979818Completed/recruiting/ongoing/terminated, depending on indicationMost extensively investigated neuro-targeted repurposed agent; primarily evaluated for modulation of sympathetic signaling and tumor-promoting stress responsesKennedy OJ et al., Eur J Cancer 2022 [139]; Hicks BM et al., Ann Oncol 2013 [144]; Fjæstad KY et al., Oncogene 2022 [112]; Gandhi S et al., Clin Cancer Res 2021 [140]Donepezil (acetylcholinesterase inhibitor)Acetylcholinesterase (AChE)Breast cancer, SCLC, head and neck cancer, pancreatic cancerPhase 3NCT01466270, NCT00006349, NCT00656513,Completed or active, depending on tumor typeExplored mainly in cholinergic regulation–related cancer settings; clinical evidence remains tumor-specific rather than broadly generalizableFornalik M et al., Clin Exp Med 2025 [145]; Rapp SR et al., J Clin Oncol 2024 [146]Bethanechol (muscarinic agonist)Muscarinic acetylcholine receptors (mAChRs)Pancreatic cancerPhase 2NCT03572283, NCT05241249Ongoing/recruitingRepresents a strategy targeting cholinergic signaling activation; current evidence is limited to early-phase pancreatic cancer studiesWhite RA et al., Oncologist 2025 [147]; Jaguar GC et al., Radiother Oncol 2015 [148]Lidocaine (voltage-gated sodium channel modulator)Voltage-gated sodium channels (VGSCs)Breast cancer, NSCLC, pancreatic cancer, ovarian cancer, colorectal cancerPhase 4NCT02839668, ChiCTR2000030629, NCT05450055, NCT00236249, NCT01841294Completed/recruiting/ongoing/unknown, depending on settingInvestigated mainly as a perioperative or adjunctive anti-tumor intervention; potential mechanisms include inhibition of neural excitability, inflammation, and metastatic niche formationGaloș EV et al., Br J Anaesth 2020 [149]; Hou YH et al., Drug Des Devel Ther 2021 [150]ONC201 (dopamine receptor antagonist)DRD2/DRD3 antagonistAcute myeloid leukemia, neuroendocrine tumors, endometrial cancer, ovarian/fallopian tube/primary peritoneal cancerPhase 2NCT03932643, NCT03034200, NCT03485729, NCT04055649OngoingRepresents dopamine pathway intervention in oncology; currently under active investigation across both hematologic and solid tumorsAtkins SL et al., Oncologist 2023 [151]; Anderson PM et al., Clin Cancer Res 2022 [152]Fluoxetine (selective serotonin reuptake inhibitor)Serotonin signaling (5-HT)Colorectal cancer, NSCLCPhase 2NCT06225011, NCT00005850Recruiting/completedA representative serotonergic agent under evaluation for possible anti-proliferative and microenvironment-modulating effectsFisch MJ et al., J Clin Oncol 2003 [153]Escitalopram (selective serotonin reuptake inhibitor)Serotonin signaling (5-HT)Pancreatic cancerPhase 2NCT05289830NCT00536172Terminated/completedClinical translation remains preliminary; current evidence does not yet support broad oncologic applicationMusselman D et al., Neuropsychopharmacology 2013 [154]; Lydiatt WM et al., JAMA Otolaryngol Head Neck Surg 2013 [155] Clinical translation of neuro-immune-targeted agents in oncology NCT05289830 NCT00536172 In contrast, most other neuroactive drugs remain at an exploratory stage, with limited mechanistic support and clinical evidence. For example, cholinergic modulators (e.g., donepezil and bechol) have been clinically evaluated in some tumors, but their effects on tumor immunity are bidirectional: activation of nAChRs generally suppresses antitumor immunity, whereas mAChR signaling may exert antitumor effects under specific conditions [113]. Lidocaine has demonstrated anti-inflammatory and antimetastatic potential primarily in perioperative settings, improving the postoperative microenvironment by inhibiting NET formation and inflammatory mediator release. Direct evidence supporting its ability to consistently enhance ICI efficacy remains lacking [156]. Dopamine receptor antagonists (e.g., ONC201) and selective serotonin reuptake inhibitors (SSRIs) primarily act on intracellular signaling pathways or neurotransmitter metabolism. ONC201 exerts cytotoxic effects by activating ClpP and antagonizing DRD2 and has shown clinical activity in certain brain tumors; however, its direct effects on the immune microenvironment remain unclear [151]. The antitumor effects of SSRIs are primarily reflected in the inhibition of cell proliferation or modulation of chemotherapy sensitivity rather than in direct neuro-immune regulation [157]. Therefore, evidence supporting these drugs as immunotherapy-sensitizing strategies remains limited. Overall, the key to repurposing neuroactive drugs lies in identifying strategies that specifically target the neuro-immune-tumor axis rather than indiscriminately expanding drug classes. Current evidence supports β-adrenergic blockade as a primary research direction, although its clinical benefit depends on multiple factors, including tumor type, degree of sympathetic activation, β-receptor expression profiles, and baseline immune characteristics of the TME. Future studies should integrate multi-omics data to systematically evaluate tumor innervation, immune infiltration, and checkpoint expression profiles and to develop a neuro–immune classification system capable of predicting treatment responses, thereby enabling the precise application of neuroactive drugs in cancer therapy. Anti-neurogenesis therapy Tumor-induced neurogenesis and axonal infiltration are important drivers of tumor progression, promoting tumor cell proliferation, invasion, and distant metastasis while contributing to the establishment of an immunosuppressive tumor microenvironment by regulating immune cell recruitment and function [81]. Therefore, anti-neurogenesis therapies targeting tumor–nerve interactions represent a dual strategy that simultaneously interferes with tumor biology and neurogenically driven immune regulation, offering potential translational value. Currently, therapeutic strategies targeting the neurotrophic factor axis (NGF/BDNF–Trk) have a well-defined biological basis, although clinical translation remains at an early stage. NGF/TrkA and BDNF/TrkB signaling pathways play central roles in tumor-associated neurogenesis and axon guidance and promote metabolic reprogramming (e.g., enhancement of the Warburg effect), anti-apoptotic capacity, and invasive phenotypes in tumor cells through activation of PI3K/AKT and MAPK pathways [158]. Previous studies show that tanezumab reduces the neuroinvasive potential of pancreatic cancer by inhibiting NGF/TrkA signaling [159], whereas Trk inhibitors such as K252a induce apoptosis and inhibit invasion in hepatocellular carcinoma (HCC) models [160]. However, most of this evidence is derived from in vitro and animal studies. Moreover, NGF/BDNF signaling plays a critical role in maintaining normal nervous system homeostasis, suggesting that its therapeutic window may be constrained by neurotoxicity and dose-dependent effects. High-quality clinical studies supporting its widespread application remain lacking. In contrast, strategies targeting the neural guidance molecule Netrin-1 show more direct potential in suppressing tumor progression. Netrin-1 participates in axon chemotaxis and regulates cell survival signaling through receptors such as DCC and UNC5, thereby inhibiting receptor-dependent apoptosis and promoting tumor cell survival, invasion, and metastasis [147, 148]. The anti-Netrin-1 antibody NP137 demonstrates preliminary efficacy in early clinical studies by inhibiting epithelial-mesenchymal transition (EMT), reducing metastatic burden, and enhancing tumor cell sensitivity to chemotherapy [149, 150]. In a phase I trial involving 14 patients with advanced esophageal cancer, 8 patients (57.1%) achieved stable disease (SD) and 1 patient (7.1%) achieved partial response (PR) according to RECIST v1.1 criteria. Target lesions were reduced by 51.16% at 6 weeks, with a maximum reduction of 54.65% observed at 6 months [149]. These findings suggest that Netrin-1 targeted therapy exerts anti-invasive and sensitizing effects by simultaneously modulating neural guidance signaling, EMT, and treatment resistance pathways. However, the available evidence is primarily derived from early-stage studies with small sample sizes and remains insufficient to demonstrate long-term survival benefits. Given that Netrin-1-related signaling is also involved in normal tissue homeostasis and neurological function, larger-scale clinical studies are required to further evaluate its efficacy, safety, and target patient populations. Although some nonspecific anti-inflammatory or metabolic modulators, such as COX-2 inhibitors, have been reported to affect neurogenesis, their antitumor effects are more likely attributable to inflammation regulation rather than direct inhibition of neuro-tumor interactions. For example, meloxicam enhances immunotherapy sensitivity through the microRNA-200/PD-L1 pathway [152], but its mechanism primarily involves immune checkpoint regulation rather than specific inhibition of neurogenesis. Therefore, classifying such drugs as anti-neurogenesis therapies remains conceptually uncertain, and their positioning within this field requires further clarification. Overall, the central challenge of anti-neurogenesis therapy lies in inhibiting tumor-associated neural remodeling while preserving normal neural function. Existing evidence supports the high translational potential of targeting tumor-selective neural signals such as Netrin-1, whereas strategies that broadly inhibit neurotrophic factors face a trade-off between safety and efficacy. Future studies should focus on: (1) elucidating dominant neurogenesis-related signaling pathways across tumor types; (2) developing targeted agents with greater tumor specificity; and (3) evaluating their synergistic effects on the neuro–immune–tumor axis in combination with immunotherapy to facilitate translation from mechanistic insights to precise clinical applications. miRNA/siRNA-based therapy RNA interference (RNAi) therapy provides a promising approach for precise regulation of the neuro-immune-tumor network by specifically silencing key pathogenic genes. Unlike traditional small molecules or antibody-based therapies, RNAi directly targets upstream regulatory nodes, enabling multi-level intervention in neurotransmitter secretion, stress signaling, and immunosuppressive pathways. However, current research remains largely focused on mechanistic exploration, and the translational potential of different targets varies substantially. Current evidence indicates that RNAi strategies targeting neurotransmitter secretion and stress-related signaling pathways have a well-defined mechanistic basis but remain primarily at the preclinical stage. IA-2 (PTPRN), a key component of dense-core vesicles (DCVs), is involved in the secretion of neurotransmitters such as acetylcholine, dopamine, and norepinephrine [153]. In small cell lung cancer (SCLC), IA-2 knockdown via RNAi or transfection with miR-342 mimics significantly reduces autocrine acetylcholine levels in tumor cells, thereby inhibiting autocrine growth signaling [154]. Dual-specificity phosphatase 1 (DUSP1) has been identified as a key mediator of norepinephrine-induced chemoresistance in ovarian cancer models. RNAi-mediated silencing of DUSP1 enhances the antitumor effects of paclitaxel and increases tumor cell apoptosis by restoring JNK/p38-mediated apoptotic signaling [155]. NGF-induced upregulation of exosomal miR-21-5p promotes perineural invasion (PNI) in pancreatic cancer, whereas inhibition of miR-21-5p partially reverses this process [158]. However, it should be noted that the primary evidence supporting these strategies is derived from in vitro and animal studies, and their antitumor effects lack clinical validation. Unlike neuroactive drugs discussed in The repurposing of neuroactive drugs section, RNAi is not an off-the-shelf therapeutic, and its clinical translation depends on both target selection and the efficacy and safety of delivery systems. Liver-targeted RNAi drugs have been approved by the U.S. Food and Drug Administration (FDA) and are in clinical use (e.g., patisiran and inclisiran), whereas tumor-targeted RNAi therapies still face substantial challenges. Currently, the major bottlenecks of RNAi therapy include low in vivo delivery efficiency, poor nucleic acid stability, and potential nonspecific immune activation [159]. In addition, extracellular matrix barriers and intratumoral heterogeneity may limit effective RNAi-mediated gene silencing in target cells. Therefore, from the perspective of evidence strength and translational feasibility, RNAi strategies remain exploratory interventions with strong mechanistic support but limited clinical feasibility. To overcome these limitations, current research focuses on developing targeted nanocarriers, local delivery strategies, and controlled-release systems to improve tissue specificity and prolong the in vivo activity of RNAi molecules [159, 160]. With advances in these technologies, RNAi is expected to progress from basic research to clinical translation and provide a novel approach for precise intervention. Tumor denervation Tumor denervation refers to the blockade of tumor-promoting neural signaling through physical or chemical approaches, thereby disrupting the neuro-immune axis and remodeling the TME. Increasing evidence indicates that PNI is a critical route of tumor dissemination and, at the same time, a major source of immunosuppression, leading to reduced CD8⁺ T cell and Th1 cell infiltration and enhanced Th2 polarization through modulation of cytokine secretion and immune cell recruitment. Consequently, this process promotes the development of an immunologically “cold” tumor phenotype. Mechanistically, the primary role of denervation is to alleviate neurogenic immunosuppression and restore antitumor immunity. Among various denervation strategies, interventions targeting specific cholinergic or vagal pathways demonstrate clear potential for immune remodeling. In a PDAC model, bilateral subphrenic vagotomy disrupts PNI structures, significantly increases tumor-infiltrating CD8⁺ T cells, elevates the Th1/Th2 ratio, and improves survival [161]. Similarly, in the ApcMin/+ mouse model, vagal denervation, but not sympathetic denervation, suppresses tumorigenesis, highlighting functional heterogeneity among neural subtypes in tumor progression [162]. These findings indicate that the antitumor effects of denervation depend on specific neural pathways rather than denervation per se and reflect a selective intervention within the neuro–immune regulatory network. Among chemical denervation strategies, some agents demonstrate antitumor and immunomodulatory potential. However, their mechanistic specificity and clinical feasibility vary substantially. For example, benzalkonium chloride (BAC) reduces the incidence and burden of gastric adenocarcinoma by ablating the myenteric nerve plexus; however, its effects primarily depend on local nerve destruction and tissue remodeling and lack a clearly defined immunoregulatory mechanism [163]. In contrast, botulinum toxin type A1 (BoNT/A1) reduces MDSCs and Tregs accumulation and promotes CD4⁺ and CD8⁺ T cell infiltration by inhibiting cholinergic neurotransmitter release. It exhibits synergistic effects when combined with anti-PD-1 therapy [164]. These findings suggest that functional denervation strategies targeting specific neurotransmitter pathways are more suitable for immunotherapy sensitization than approaches relying solely on structural nerve destruction. Nonspecific denervation methods, including radiofrequency, electromagnetic approaches, or nonselective chemical insults, are primarily used for tumor-related pain control and have limited evidence supporting direct antitumor effects [165]. Although these methods reduce local nerve input, their lack of selective blockade of tumor-promoting neural signals results in uncertain effects on TME immune status and limits their ability to achieve stable and predictable antitumor outcomes. Overall, the efficacy of tumor denervation strategies depends on the balance among neural subtype selectivity, immunomodulatory capacity, and safety. Current evidence supports that functional denervation targeting cholinergic or vagal pathways has potential for immune remodeling and ICIs sensitization, whereas generalized or nonselective denervation is limited by variable efficacy and potential neurological toxicity. Future studies should focus on: (1) identifying key neural driver pathways across tumor types; (2) developing highly selective neuromodulation strategies to minimize off-target effects; and (3) systematically evaluating the synergistic mechanisms and responsive patient populations for denervation combined with immunotherapy to facilitate translation from experimental research to precise clinical application. Cell therapy Cell therapy, particularly CAR-T cells, represents a novel approach for targeting the neuro-immune axis. Unlike conventional targeted therapies, CAR-T cells directly mediate tumor cell killing and modulate the TME through cytokine release and immune remodeling. However, the application of CAR-T therapy to neurally related targets remains at an early exploratory stage, with substantial variability in efficacy and translational potential across different strategies. Current studies indicate that CAR-T strategies targeting TRKB (NTRK2) have a well-defined mechanistic basis, although their efficacy is significantly limited by TME-associated immunosuppression. As a high-affinity receptor for BDNF, TRKB is aberrantly overexpressed in various tumors, promoting tumor cell proliferation, invasion, and resistance to apoptosis through activation of PI3K/Akt, MAPK, and related pathways, while also contributing to neuro-tumor interactions and drug resistance [166]. Based on these findings, TRKB-specific CAR-T cells have been developed using BDNF or NTF4 as recognition domains. In HCC and pancreatic cancer models, both BDNF-CAR-T and NTF4-CAR-T cells exhibit dose-dependent cytotoxicity against TRKB-high tumor cells, accompanied by increased IFN-γ and other cytokine release [167]. Further studies show that TRKB overexpression enhances tumor cell sensitivity to CAR-T–mediated killing, indicating strong target dependence of this strategy. However, differences in efficacy among CAR-T constructs highlight the critical limiting effect of TME-associated immunosuppression on this strategy. In a murine HCC model, NTF4-CAR-T significantly inhibits tumor growth, whereas BDNF-CAR-T shows limited efficacy; this difference is attributed to T cell exhaustion associated with PD-L1 upregulation during treatment [168]. These findings suggest that TRKB-targeting CAR-T alone is insufficient to overcome TME immunosuppression and that its efficacy depends on immune checkpoint status. Therefore, TRKB-targeting CAR-T is more likely to be used as part of combination immunotherapy, such as with PD-1/PD-L1 inhibitors, rather than as a standalone treatment. In terms of safety, potential “on-target, off-tumor” toxicity of TRKB-targeting CAR-T requires careful evaluation. Although TRKB is highly expressed in the nervous system, the ligand–receptor binding affinity of BDNF-CAR-T and NTF4-CAR-T is lower than that of typical antibody–antigen interactions, which may reduce off-target risk to some extent [169]. Previous studies show that these CAR-T constructs exhibit limited cytotoxicity toward cells with low or absent TRKB expression, with no significant weight loss or behavioral abnormalities observed in animal models [167]. However, given the physiological importance of TRKB in the central and peripheral nervous systems, data on long-term safety and potential neurotoxicity remain limited. In addition, CAR-T–related adverse events, such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), may present more complex manifestations in the context of neural targets. Overall, TRKB-targeting CAR-T represents a class of neurally relevant cellular therapies with well-defined mechanisms but limited by the TME. Its antitumor efficacy depends on target expression levels and the immune microenvironment rather than antigen recognition efficiency alone. Future studies should focus on: (1) improving CAR-T cell persistence and function through combination with ICIs or TME-modulating strategies; (2) optimizing CAR constructs (e.g., incorporating costimulatory domains or safety switches) to balance efficacy and safety; and (3) selecting patient populations with high TRKB expression and low immunosuppression. Oncolytic virotherapy Oncolytic viruses (OVs) demonstrate unique advantages in tumor therapy by selectively infecting and lysing tumor cells while inducing immunogenic cell death (ICD) and antitumor immune activation. However, their clinical application has been limited by low in vivo delivery efficiency, rapid clearance by the host immune system, and heterogeneous intratumoral distribution. In this context, leveraging the tumor tropism of neural stem cells (NSCs) as OV delivery vectors represents a promising strategy for translational optimization. NSCs can migrate across the BBB and actively home to tumor sites. NSC tropism is primarily mediated by the CXCR4/CXCL12 axis and inflammation-related chemotactic signals. Therefore, the NSC-OV strategy exerts antitumor effects through a triple mechanism involving cell delivery, viral lysis, and immune activation. The FDA-approved immortalized NSC line HB1.F3.CD21 provides a stable cellular platform for delivering CRAd-S-pk7, a survivin promoter–driven, pk7 fiber-modified conditionally replicative adenovirus, thereby enabling selective tumor infection and local viral amplification [170, 171]. NSC-loaded OV delivery demonstrates efficacy advantages in preclinical models. In an orthotopic glioma model, intracranial injection of NSCs loaded with CRAd-S-pk7 significantly prolongs survival compared with administration of the virus alone [172]. This advantage reflects the tumor-homing capacity of NSCs, which increases local viral concentration and partially overcomes systemic delivery barriers. In addition, NSCs enhance viral replication and immune activation by modulating the local inflammatory microenvironment. However, early clinical studies suggest that the antitumor effects of this strategy remain limited, with no statistically significant benefit observed. In a study involving 11 patients with glioblastoma and one with anaplastic astrocytoma, NSC-loaded CRAd-S-pk7 combined with standard therapy showed no dose-limiting toxicity, indicating an acceptable safety profile. However, PFS and overall survival (OS) were only modestly improved compared with historical controls and did not reach statistical significance [173]. These findings suggest that although NSC delivery improves viral localization, oncolysis alone is insufficient to overcome the highly immunosuppressive TME. Application of this strategy in other tumor types further highlights its advantages and limitations. In an ovarian cancer model, intraperitoneal administration of NSC-delivered CRAd-S-pk7 effectively inhibits tumor growth and prevents viral neutralization by circulating antibodies. When combined with cisplatin, its antitumor efficacy is further enhanced [174]. This observation suggests that the NSC–OV strategy is better suited as a combination therapy platform rather than a standalone treatment. Moreover, administration routes significantly influence efficacy: in ovarian cancer, intraperitoneal delivery is superior to intravenous administration, which is limited by cell size and pulmonary capillary trapping. Although NSCs exhibit greater migratory capacity than mesenchymal stem cells (MSCs), overall delivery efficiency remains limited [175, 176]. Mechanistically, the key bottleneck of the NSC–OV strategy lies not in the virus itself but in delivery efficiency and immune regulatory capacity. Although NSCs exhibit tumor tropism, their homing efficiency and intratumoral distribution remain insufficient to achieve uniform infection. In addition, immune responses induced by oncolytic viruses enhance antitumor effects but may also limit sustained viral replication through type I interferon–mediated antiviral immunity. Therapeutic efficacy therefore depends on a kinetic balance among viral infectivity, host antiviral immunity, immune-cell recruitment, and sustained viral replication. Overall, NSC-mediated oncolytic virotherapy represents a therapeutic modality with optimized delivery, although its efficacy remains dependent on combination strategies. Key considerations for clinical translation include: (1) enhancing tumor-specific homing of NSCs; (2) optimizing viral design to prolong in vivo replication and enhance immunogenicity; and (3) combining with immune checkpoint inhibitors or chemotherapy to overcome immunosuppressive barriers in the TME. Behavioral regulation Behavioral regulation systemically influences tumor progression through the neuroendocrine–immune network and represents an important exogenous factor modulating the neuro–immune axis. However, compared with pharmacological or cell-based therapies, its antitumor effects are primarily reflected in modulation of the immune microenvironment and therapeutic sensitization rather than direct tumor cell killing. Stress regulation is considered an important upstream factor influencing tumor immunity. It represents a physiological and emotional response to life challenges and is primarily regulated by the nervous system. Physical activity and mindfulness- or cognitive-based interventions, such as yoga, tai chi, and meditation, reduce stress and induce changes that support antitumor immunity, including decreased inflammation, enhanced Th1 responses, and increased NK cell activity [177]. In patients with nonmetastatic breast cancer, psychological interventions administered before surgery and adjuvant therapy significantly reduce the risk of death or recurrence [178] while improving quality of life and subjective well-being [179]. In liver cancer models, beneficial stress (eustress) enhances sensitivity to immunotherapy. This effect may involve activation of the peripheral sympathetic nervous system, increased norepinephrine and epinephrine levels in serum and tumor tissues, and subsequent activation of β-adrenergic signaling in tumor cells and tumor-infiltrating myeloid cells. This pathway downregulates CCL2 expression in tumor and immune cells, reduces TAM and MDSC infiltration in the TME, and enhances CD8⁺ T-cell infiltration and function, thereby improving sensitivity to anti-PD-L1 therapy and other ICIs [180]. Some psychotropic drugs exhibit immunostimulatory effects, including adjuvant antitumor activity through modulation of intratumoral lymphocytes. In patients with triple-negative breast cancer, the use of psychotropic agents is associated with higher rates of pathological complete response [181]. In summary, stress management regulates immune function through multiple pathways and may improve cancer treatment outcomes. However, most available clinical data are correlational, and substantial heterogeneity in intervention approaches and patient populations limits their ability to support stress management as an independent antitumor strategy. Instead, it is more appropriately considered an adjunct immunomodulatory approach. Exercise is supported by relatively consistent evidence as a behavioral immunomodulatory strategy, with antitumor effects mediated primarily through immune mechanisms. Clinical and preclinical studies demonstrate that regular physical activity improves immune status by modulating inflammation, enhancing NK cell activity, and promoting CD8⁺ T cell function [182–184]. Furthermore, behavioral interventions such as physical activity, stress management, and sleep optimization improve treatment tolerance and psychological status and may indirectly influence tumor progression through immune regulation. Several mouse studies have explored the potential synergistic effects of exercise combined with ICIs in tumor therapy [185]. In a patient-derived xenograft model of NSCLC, anti-PD-1 therapy combined with exercise increases tumor necrosis and reduces apoptosis, suggesting enhanced therapeutic efficacy [186]. Another study shows that aerobic exercise (30 min/day treadmill training) improves the sensitivity of pancreatic tumors to anti-PD-1 therapy through IL-15Rα⁺ CD8⁺ T cell–mediated antitumor immunity, ultimately slowing tumor growth [187]. In a breast tumor model treated with anti-PD-1, voluntary rotarod exercise increases tumor-infiltrating CD8⁺ T cells, whereas no similar change is observed in sedentary controls [188]. Nonetheless, current evidence is primarily derived from preclinical studies, and variations in exercise modality, intensity, and duration result in distinct immunological effects. Thus, exercise intervention is better suited as an adjunctive sensitization strategy for immunotherapy rather than a standardized antitumor treatment. Circadian rhythm regulation represents one of the most promising directions for the clinical translation of behavioral interventions. Circadian rhythms are intrinsic timekeeping systems regulated by the nervous system that coordinate physiological and behavioral processes, including sleep–wake, feeding–fasting, and activity–rest cycles. Sleep deprivation or circadian disruption impairs immune function and weakens tumor surveillance and clearance. Meanwhile, physiological activity and psychological stress during wakefulness influence immune cell function via neuroendocrine pathways, thereby modulating antitumor immune responses [189]. Clinical studies show that, in advanced lung cancer, morning administration of anti-PD-1 therapy yields greater efficacy than afternoon administration [190], suggesting dependence on circadian fluctuations in CD8⁺ T cells. Therefore, optimizing the timing of ICI administration according to circadian rhythms may improve therapeutic outcomes [136]. Similarly, circadian-guided radiotherapy and chemotherapy may improve efficacy while reducing adverse effects [191]. In addition, RORγ, a nuclear receptor family member, regulates core circadian genes such as BMAL1, CLOCK, and REV-ERBα/β. Preclinical studies show that RORγ agonists enhance antitumor immunity in CAR-expressing Th17 cells and provide long-term tumor protection [192]. A clinical trial evaluating RORγ agonists combined with anti-PD-1 therapy in metastatic NSCLC (NCT03396497) is ongoing. Unlike stress and exercise interventions, circadian regulation offers a defined temporal intervention window without additional treatment burden, making it more clinically feasible. However, current evidence is largely based on retrospective analyses or small sample studies, and the optimal timing and target populations remain unclear. In conclusion, behavioral regulation influences tumor progression through multilevel neuro–immune mechanisms, although its antitumor effects are indirect, context-dependent, and subject to interindividual variability. Existing evidence supports its use as an adjunct to immunotherapy rather than as a standalone treatment. Among these approaches, circadian optimization appears most readily translatable, whereas exercise and stress management currently serve mainly as supportive immunomodulatory strategies. Future studies should focus on: (1) elucidating how specific behavioral interventions affect defined immune-cell subsets; (2) evaluating synergy between behavioral interventions and ICIs; and (3) developing precision strategies based on individual circadian and neural states to promote the transition from empirical supportive care to mechanism-guided adjunctive therapy. Prospects and challenges in cancer neuroscience Recent studies in tumor neurobiology reveal that interactions between tumor cells and the nervous system extend beyond traditional concepts of tumor innervation and significantly influence therapeutic outcomes. These findings provide a rationale for developing innovative therapeutic strategies. For example, cancer-induced neural damage has been identified as a key mechanism that promotes local immunosuppression and resistance to anti-PD-1 immunotherapy, highlighting the central role of the nervous system in modulating therapeutic responses [193]. Targeting neural signaling pathways, such as metabotropic glutamate receptor 4 (mGluR4), may reshape the TME and enhance antitumor immunity [194]. Future research should define how tumors communicate with adjacent neural structures and how these signals shape tumor progression and therapeutic response within the TME. An important aspect of this interaction is the impact of neural invasion on tumor metabolic reprogramming, which in turn influences immunotherapy efficacy in tumors such as non-small cell lung cancer [195]. Meanwhile, the identification of novel biomarkers and therapeutic targets related to tumor-associated neural connections provides opportunities for the development of targeted therapies [196]. Furthermore, pharmacological interventions targeting nerve–tumor crosstalk enhance the efficacy of standard chemotherapy in pancreatic cancer, supporting this axis as a viable therapeutic target [197]. Targeting key elements of nerve–tumor interactions may disrupt signaling pathways involved in tumor proliferation and metastasis, thereby inhibiting tumor progression. Nevertheless, tumor neurobiology faces several technical challenges, including the lack of diagnostic tools capable of precisely visualizing and quantifying neural infiltration within tumors [198]. Although existing imaging techniques provide anatomical and functional information, their sensitivity and specificity remain insufficient, limiting comprehensive assessment of tumor neurobiology. Moreover, substantial heterogeneity in neurobiological features across tumor types makes the development of individualized treatment strategies challenging [199]. To address this challenge, advanced genomics, proteomics, and imaging technologies should be integrated to characterize tumor–nervous system interactions at the molecular level through multidimensional approaches. Interdisciplinary collaboration is essential for advancing tumor neurobiology. Tumor–nerve interactions span multiple disciplines and require integration of expertise from oncology, neuroscience, immunology, bioengineering, and computational biology [200]. Such collaboration will integrate diverse expertise, facilitate innovative diagnostic development, improve therapeutic targeting accuracy, and accelerate translation from basic research to clinical application. Conclusion As the TME has become recognized as a central driver of cancer initiation and progression, the nervous system has emerged as a major regulatory dimension in cancer biology. Advances in cancer neuroscience have further expanded mechanistic and translational understanding of this regulatory axis. Innervation and neuro–immune crosstalk remodel immune cell phenotype and function through signaling mediators such as neurotransmitters and neuropeptides, thereby driving the formation of an immunosuppressive microenvironment and promoting tumor immune escape, progression, and metastasis. In particular, adrenergic, cholinergic, and nociception-related signaling pathways play key roles in regulating antitumor immunity and influencing responses to immunotherapy. Nonetheless, significant research challenges remain. Neuromodulatory interventions, including drug repurposing strategies such as β-blockers, are supported by preclinical and retrospective clinical evidence. However, their effects remain highly heterogeneous, indicating that neuromodulation of tumor immunity is strongly context-dependent. Moreover, single-pathway interventions are insufficient to reverse complex immunosuppressive networks, thereby limiting their clinical translational potential. Future studies should integrate mechanistic dissection of neuro–immune heterogeneity with biomarker-driven stratification to identify patients most likely to benefit from neuromodulatory combination therapies. In addition, multidisciplinary approaches integrating neuroscience, immunology, and oncology are essential for constructing neuro–immune–tumor interaction networks and promoting clinical translation. Overall, systematic analysis of the neuro–immune axis will define an upstream regulatory framework for tumor immunity and provide a practical basis for optimizing immunotherapy and developing personalized interventions.